At Novo Nordisk we are committed to conducting our business in a financially, environmentally and socially responsible way. As climate change has global implications on all three dimensions, and poses a significant threat to human health and development, taking steps to reduce our impact is both an act of long-term risk mitigation and corporate responsibility.
Recognising that climate change - as the diabetes pandemic - is related to the consumption and lifestyle trends of high and middle income economies, climate change is also an unprecedented opportunity to bring the world on a healthier, more sustainable course.
Novo Nordisk's position
In the scientific debate, Novo Nordisk refers to the findings of the UN Intergovernmental Panel of Climate Change.
Business must help mitigate climate change by:
- Mapping its direct and indirect footprint and report on performance
- Pursuing a green growth strategy: Set ambitious absolute reduction target for emissions, increase energy-efficiency in countries of operation and promote renewable energy sources
- Innovating, developing and sharing new business models, technologies and processes
- Advocating for an ambitious, global and fair agreement to replace the Kyoto Protocol
- Encouraging employees to lead sustainable lives.
Climate action in Novo Nordisk
Novo Nordisk's climate strategy is developed in accordance with the Greenhouse Gas Protocol. It includes all scope 1 and 2 emissions within operational control and scope 3 emissions that are significant in size or significant from a stakeholder perspective. Towards 2020 our focus is on reporting and reducing emissions from global production sites, company cars, product distribution and business travel.
Recognising the complexity and cross cutting nature of climate change, Novo Nordisk has taken a partnership approach to address this global challenge:
- In 2006 Novo Nordisk became a member of the World Wide Fund for Nature (WWF) Climate Savers programme. Under this programme Novo Nordisk has committed to reduce CO2 emissions from global production sites by 10% from 2004 to 2014 while growing our business.
- In May 2007, Novo Nordisk signed a partnership agreement with the Danish energy company DONG Energy. Under the partnership, Novo Nordisk pledges to convert all energy savings realised at its Danish production sites into the purchase of electricity from a new wind farm in the North Sea. By 2010 Novo Nordisk's production facilities in Denmark, including the energy-intensive insulin production, will be powered entirely by wind energy.
- Novo Nordisk is a signatory to the The UN Global Compact: Caring for Climate Leadership platform and The Bali Communiqué, The Poznan Communiqué, The Copenhagen Communiqué and The Cancun Communiqué of the Prince of Wales' Corporate Leaders Group.